scholarly journals Biatrial versus Isolated Left Atrial Ablation in Atrial Fibrillation: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-14
Author(s):  
Hongmu Li ◽  
Xifeng Lin ◽  
Xun Ma ◽  
Jun Tao ◽  
Rongjun Zou ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Sinus Rhythm ◽  
Left Atrial ◽  
Meta Analysis ◽  
Pacemaker Implantation ◽  
Permanent Pacemaker ◽  
Risk Of Death ◽  
Permanent Pacemaker Implantation ◽  
Atrial Ablation ◽  
Significant Difference

Objective. The outcomes of biatrial ablation (BA) and isolated left atrial ablation (LA) in atrial fibrillation remain inconclusive. In this meta-analysis, we assess the currently available evidence to compare outcomes between BA and LA.Methods. Electronic searches were performed from database inception to December 2016, and relevant studies were accessed. Odds ratios and weight mean differences with 95% confidence intervals are reported. Twenty-one studies comprising 3609 patients were included in the present meta-analysis.Results. The prevalence of sinus rhythm in the BA cohort was similar to that in the LA cohort at discharge, at 12 months, and after more than 1 year of follow-up. However, at 6 months, the prevalence of sinus rhythm was higher in the BA cohort than in the LA cohort. The rate of permanent pacemaker implantation was higher in the BA cohort than in the LA cohort. However, 30-day and late mortality and neurological events were similar between the BA and LA groups.Conclusion. There was no significant difference in the rate of restored sinus rhythm, the risk of death, and cerebrovascular events between BA and LA, but BA had a higher rate of permanent pacemaker implantation.

scholarly journals Predictors for permanent pacemaker implantation after concomitant surgical ablation for atrial fibrillation

2014 ◽  
Vol 147 (3) ◽  
pp. 984-988 ◽  
Author(s):  
Simon Pecha ◽  
Timm Schäfer ◽  
Yalin Yildirim ◽  
Teymour Ahmadzade ◽  
Stephan Willems ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Pacemaker Implantation ◽  
Permanent Pacemaker ◽  
Surgical Ablation ◽  
Permanent Pacemaker Implantation

scholarly journals Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis

EP Europace ◽  
2019 ◽  
Vol 21 (8) ◽  
pp. 1159-1166 ◽  
Author(s):  
William F McIntyre ◽  
Jeff S Healey ◽  
Akash K Bhatnagar ◽  
Patrick Wang ◽  
Jacob A Gordon ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Sinus Rhythm ◽  
Meta Analysis ◽  
Structural Heart Disease ◽  
Quality Of Evidence ◽  
Recent Onset ◽  
Assessment Development ◽  
Significant Difference ◽  
Pharmacological Cardioversion

AbstractAimsTo evaluate the efficacy and safety of vernakalant for the cardioversion of atrial fibrillation (AF).Methods and resultsWe reviewed the literature for randomized trials that compared vernakalant to another drug or placebo in patients with AF of onset ≤7 days. We used a random-effects model to combine quantitative data and rated the quality of evidence using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation). From 441 total citations in MEDLINE, EMBASE, and CENTRAL (December 2018), we identified nine trials evaluating 1358 participants. Six trials compared vernakalant to placebo, two trials compared vernakalant to ibutilide, and one trial compared vernakalant to amiodarone. We found significant methodological bias in four trials. For conversion within 90 min, vernakalant was superior to placebo [50% conversion, risk ratio (RR) 5.15; 95% confidence interval (CI); 2.24–11.84, I2 = 91%], whereas we found no significant difference in conversion when vernakalant was compared with an active drug (56% vs. 24% conversion, RR 2.40; 95% CI 0.76–7.58, I2 = 94). Sinus rhythm was maintained at 24 h in 85% (95% CI 80–88%) of patients who converted acutely with vernakalant. Overall, we judged the quality of evidence for efficacy to be low based on inconsistency and suspected publication bias. There was no significant difference in the risk of significant adverse events between vernakalant and comparator (RR 0.95; 95% CI 0.70–1.28, I2 = 0, moderate quality evidence). Vernakalant is safe and effective for rapid and durable restoration of sinus rhythm in patients with recent-onset AF.ConclusionVernakalant should be a first line option for the pharmacological cardioversion of patients with haemodynamically stable recent-onset AF without severe structural heart disease.

scholarly journals Cox-maze III Procedure for Atrial Fibrillation during Valve Surgery: A Single Institution Experience

2020 ◽  
Author(s):  
Changtian Wang ◽  
Lei Zhang ◽  
Tao Qin ◽  
Zhi-long Xi ◽  
Lei Sun ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Sinus Rhythm ◽  
Pacemaker Implantation ◽  
Permanent Pacemaker ◽  
Valve Surgery ◽  
Valve Disease ◽  
Heart Valve Disease ◽  
Efficacy And Safety ◽  
Single Institution ◽  
The Mean

Abstract Objectives Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in patients with heart valve disease. Our aim was to summarize our experience and evaluate the efficacy and safety of the Cox maze III procedure combined with valve surgery in patients with AF. Methods A retrospective, observational analysis was performed for all consecutive patients underwent maze III procedure combined with valve surgery between October 2015 and June 2019. Results 66 patients (37 female, 56.1%) with persistent or long-lasting persistent AF associated with valve disease were identified. The mean age was 54.2±8.4 years (range, 30 to 73 years). Overall hospital mortality was 3.0%. The duration of cardiopulmonary bypass and aortic cross clamping was 175.4±32.9 and 115.6±22.8 minutes respectively. The first 24hours drainage was 488.6±293.3ml. The postoperative hospital stay was 14.8±8.3 days. The postoperative incidence of permanent pacemaker implantation, reoperation for bleeding, renal failure required hemodialysis, and stroke was 4.5%, 1.5%, 4.5% and 0 respectively. The frequency of sinus rhythm was 91.7%, 93.1%, 94.5%, 92.9% and 91.4% at 1, 3, 6, 12, and 24 months respectively. Conclusions The Cox-Maze III procedure is safe in the surgical treatment of AF associated with valve disease, and efficacious for sinus rhythm maintenance, with low morbidity and mortality.

Sign in / Sign up

Export Citation Format

Share Document